H. Lewis

发表

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

C. Brander, V. Miller, T. Peto, 2021, Cell reports.

Improving ascertainment and treatment rates of chronic viral hepatitis

H. Lewis, 2017 .

Localised community circulation of SARS-CoV-2 viruses with an increased accumulation of single nucleotide polymorphisms that adversely affect the sensitivity of real-time reverse transcription assays targeting Nucleocapsid protein.

T. Connor, S. Corden, A. Barratt, 2021, medRxiv.

A large outbreak of COVID-19 in a UK prison, October 2020 to April 2021

C. Moore, D. Thomas, A. Waldram, 2022, Epidemiology and Infection.

Laboratory-based surveillance of Campylobacter and Salmonella infection and the importance of denominator data

J. Janiec, D. Thomas, M. Evans, 2012, Epidemiology and Infection.

Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment

G. Foster, J. Dalton, H. Lewis, 2016, European journal of gastroenterology & hepatology.

Other liver viruses

G. Foster, W. Alazawi, H. Lewis, 2011 .

Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.

G. Foster, H. Lewis, M. Cunningham, 2012, Best practice & research. Clinical gastroenterology.

A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study

J. Frater, S. Fidler, G. Timson, 2017, Scientific Reports.

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

M. Johnson, V. Miller, T. Peto, 2020, The Lancet.

903 WHAT IS THE BEST METHOD OF CASE FINDING FOR CHRONIC VIRAL HEPATITIS IN AT-RISK MIGRANT COMMUNITIES?

G. Foster, S. Begum, K. Burke, 2012 .

Telaprevir: evidence and guidance for use in clinical practice

G. Foster, H. Lewis, 2013 .

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

C. Brander, V. Miller, T. Peto, 2020, SSRN Electronic Journal.